Home > Protocol Summaries: Compounds > GSK2245840 Protocol Summaries: GSK2245840 GSKStudy ID Phase Title Status 113259 phase 1 A Phase I Randomized, Placebo-Controlled, Single-Blind, Multiple-Dose, Dose-Escalation Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers Completed 113260 phase 1 Evaluation of the pharmacokinetics and the absolute bioavailability of SRT2104 given as a 250mg oral suspension and intravenous microdose of 100 µg Carbon-14 radio-labeled SRT2104 in healthy male subjects Completed 114296 phase 2 A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects with Moderate to Severe Plaque-Type Psoriasis Completed 115951 phase 1 A Phase 1b, Exploratory Study to Assess the Safety, Tolerability, Colonic Tissue Exposure, and Anti-Inflammatory Effects of Two Different Doses of SRT2104 in Subjects with Mild to Moderate Ulcerative Colitis Recruiting
